OncoSec Medical Inc organizacji FCF yield
Jaka jest wartość FCF yield organizacji OncoSec Medical Inc?
Wartość FCF yield organizacji OncoSec Medical Inc to -483.57%
Jaka jest definicja FCF yield?
Free cash flow yield (FCF yield) is a financial ratio that compares the free cash flow per share to the market value per share. The ratio is calculated by dividing free cash flow per share by the current share price.
ttm (trailing twelve months)
Free cash flow yield is a good measure of the company’s cash flow in respect to the company’s size. Larger companies tend to have a higher cash flow yield, but it’s not always the case. The higher the free cash flow yield, the more cash the company is generating that can be quickly accessed to satisfy its obligations. The lower the free cash flow yield, the more money investors are putting into the company with little result. The higher the ratio, the more attractive the investment is as it suggests that investors are paying less for each unit of free cash flow.
Free cash flow acts as an indicator of how capable a company is of repaying all of its obligations. It is a solid indicator of how financially stable a company is. It is calculated as:
Free cash flow yield = Free cash flow per share / market price per share
FCF yield firm w Health Care sektor na NASDAQ w porównaniu do OncoSec Medical Inc
Czym się zajmuję organizacja OncoSec Medical Inc?
oncosec is a san diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. our technology, immunopulse™, is designed to enhance the local delivery and uptake of dna-based immune-targeting agents, such as il-12. clinical trials of immunopulse™ il-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. our lead program, immunopulse™ il-12, is currently in phase ii development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. to date, study results have laid the groundwork for the expansion into new dna-encoded therapeutic candidates and tumor indications. we ar
Firmy z fcf yield podobne do OncoSec Medical Inc
- Wartość FCF yield organizacji Winc to -518.19%
- Wartość FCF yield organizacji Exicure to -510.85%
- Wartość FCF yield organizacji Shopify to -498.72%
- Wartość FCF yield organizacji Cuda Oil and Gas to -496.54%
- Wartość FCF yield organizacji BBVA Argentina to -486.90%
- Wartość FCF yield organizacji Waitr Inc to -485.61%
- Wartość FCF yield organizacji OncoSec Medical Inc to -483.57%
- Wartość FCF yield organizacji Kiromic BioPharma to -482.25%
- Wartość FCF yield organizacji NextDecade to -481.51%
- Wartość FCF yield organizacji Silver Mountain Mines to -481.33%
- Wartość FCF yield organizacji Skyfame Realty () to -477.89%
- Wartość FCF yield organizacji EVIO to -476.77%
- Wartość FCF yield organizacji Shift Technologies to -471.17%